Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talks – National
Negotiations that could have led to coverage of weight-loss drug Wegovy under Canadian public health plans are not…
Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer’s trials
By Deena Beasley SAN DIEGO Dec 2 (Reuters) – Novo Nordisk in 2020 launched pivotal trials of its…
Updated: CMS unveils negotiated prices for Ozempic, Wegovy and other drugs from second round of IRA talks – Endpoints News
Updated: CMS unveils negotiated prices for Ozempic, Wegovy and other drugs from second round of IRA talks Endpoints NewsU.S.…
Novo Nordisk backs biotech start-up targeting aging
General Control enters Novo Nordisk’s Co-Creation Greenhouse to advance multiplex epigenetic editing for complex chronic disease. General Control,…
Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong…
Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
If approved, investigational semaglutide 7.2 mg injection would offer the optionality of a higher dose for greater weight…
Does Novo Nordisk’s (CPSE:NOVO B) Alzheimer’s Setback Challenge Its Long-Term Diversification Ambitions?
On November 24, 2025, Novo Nordisk announced top-line results from its phase 3 evoke and evoke+ trials, revealing…
Novo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 per month
For a limited time, patients in the US can get the first two doses of authentic, FDA-approved Wegovy®…
Novo Nordisk Just Saved Denmark’s Economy–But for How Long?
This article first appeared on GuruFocus. Danish GDP didn’t just rebound in the third quarterit snapped back with…
Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants’ Stocks?
Don’t look now, but the costs of America’s beloved weight loss drugs are about to come down. Way…
Who’s Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?
Eli Lilly’s GLP-1 drug is now the world’s best-selling drug. Novo Nordisk is struggling with declining market share.…
Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats
One of the most compelling acquisition sagas in the pharma industry in recent times has come to an…